Pharmaceuticals, Biotechnology and Life Sciences
Takeda got exclusive global license for investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in…
Takeda said Tuesday it will sell certain OTC and non-core assets for over $200 million to ACino, to accelerate deleveraging as it said it will simplify portfolio in Takeda’s NEMEA region.
Takeda’s presentation has shown TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo.
Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis
Crescendo Biologics has reached fifth milestone in its deal with Takeda from 2016, for using its Humabody-based therapeutics against targets which Takeda selects.
Takeda has been named in the Dow Jones Sustainabilitz World Index, having more than double the average overall industry score, the company said in a press release Wednesday, noting it was also named in Dow Jones Sustainability Asia Pacific Index for 10th Consecutive Year.
NICE has recommended the use of Takhzyro subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, within their final appraisal document (FAD), Takeda UK said in a press release Wednesday.
Sosei Group Corporationhas partnered up with Takeda to work on novel molecules, including small molecules and biologics, that modulate G protein-coupled receptor (“GPCR”) targets.
CAMBRIDGE, England–(BUSINESS WIRE)–Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical…
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress